Genmab A/S
Interim Report for the 6 months ended June 30, 2011
Genmab A/S 03.08.2011 17:31 --------------------------------------------------------------------------- - Continued strong focus on cost control with improvement in first half operating loss and cash burn over 2010 - Improving 2011 guidance as result of DKK 25 million reduction in operating expenses - Announced HuMax-CD74(TM) antibody-drug conjugate program with Seattle Genetics - Decisive move to minimize future spending by winding down the zalutumumab program In order to read Genmab's Interim Report for the 6 months ended June 30, 2011 please see the attached file. Contact: Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication T: +45 33 44 77 20 M: +45 25 12 62 60 E: r.gravesen@genmab.com www.genmab.com Company Announcement no. 24 CVR no. 2102 3884 Genmab A/S Bredgade 34 1260 Copenhagen K Denmark 03.08.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Genmab A/S Denmark Phone: Fax: E-mail: Internet: ISIN: DK0010272202 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found